SCHEMBL5879981

SCHEMBL5879981

Cc1ccc(/C=N/NC(=O)Cc2cccc(Cl)c2)c(OS(=O)(=O)c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
SGK1 O00141 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 2/20 0.44
LMNA P02545 5/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 1/20 0.43
MAPT P10636 3/20 0.43
HTT P42858 1/20 0.43
CSNK1D P48730 1/20 0.42
FFAR2 O15552 1/20 0.41
ANO1 Q5XXA6 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879984 1.00 POLB (0.46) POLBTDP1SGK1MEN1KMT2A
SCHEMBL5879945 0.93 MEN1 (0.46) POLBTDP1SGK1MEN1KMT2A
SCHEMBL5879941 0.93 MEN1 (0.46) POLBTDP1SGK1MEN1KMT2A
SCHEMBL5879764 0.91 LMNA (0.45) SGK1MEN1KMT2ANPC1LMNA
SCHEMBL5879768 0.91 LMNA (0.45) SGK1MEN1KMT2ANPC1LMNA
SCHEMBL5880262 0.90 SGK1 (0.48) POLBTDP1SGK1MEN1KMT2A
SCHEMBL5880259 0.90 SGK1 (0.48) POLBTDP1SGK1MEN1KMT2A
SCHEMBL5880163 0.90 CYP1A2 (0.49) SGK1MEN1KMT2ALMNAALDH1A1
SCHEMBL5880161 0.90 CYP1A2 (0.49) SGK1MEN1KMT2ALMNAALDH1A1
SCHEMBL5879579 0.88 SGK1 (0.47) SGK1LMNAALDH1A1MAPTCSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026339-B2 Inhibitors of HCV NS5B polymerase PFIZER INC. 2006-04-11 US disclosed
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate PHARMACIA & UPJOHN COMPANY 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate ACACB, HCCS, HAVCR2 POLB 887/4885TDP1 4826/4885SGK1 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.